NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE:INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inspire and certain of its officers and/or […]

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ:HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Harrow and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ:JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Jasper and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. ("Confluent" or the "Company") (NASDAQ:CFLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Confluent and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Insperity, Inc. ("Insperity" or the "Company") (NYSE:NSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insperity and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. ("Lineage" or the "Company") (NASDAQ:LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dow Inc. ("Dow" or the "Company") (NYSE:DOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dow and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Six Flags Entertainment Corporation ("Six Flags" or the "Company") (NYSE:FUN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Six Flags and certain of